News | May 11, 2023
FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
Mahajan Imaging, which currently has 10 high-end medical diagnostic centres in Delhi-NCR and Jaipur, has ventured into a new field called Integrated Diagnostics
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Blood contains a mixture of exosomes secreted from nearly all tissues and cells, and exosomes from other tissues can mask changes caused by disease, making it difficult to detect the presence of biomarkers that reflect disease
Subscribe To Our Newsletter & Stay Updated
